000 | 01988 a2200565 4500 | ||
---|---|---|---|
005 | 20250516072914.0 | ||
264 | 0 | _c20120612 | |
008 | 201206s 0 0 eng d | ||
022 | _a1528-0020 | ||
024 | 7 |
_a10.1182/blood-2011-06-359224 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aPascale, Silvia | |
245 | 0 | 0 |
_aAspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. _h[electronic resource] |
260 |
_bBlood _cApr 2012 |
||
300 |
_a3595-603 p. _bdigital |
||
500 | _aPublication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 | _aAcceleration |
650 | 0 | 4 | _aAdult |
650 | 0 | 4 | _aAged |
650 | 0 | 4 | _aAlgorithms |
650 | 0 | 4 |
_aAnti-Inflammatory Agents, Non-Steroidal _xtherapeutic use |
650 | 0 | 4 |
_aAspirin _xadministration & dosage |
650 | 0 | 4 | _aCross-Over Studies |
650 | 0 | 4 |
_aCross-Sectional Studies _xstatistics & numerical data |
650 | 0 | 4 |
_aCyclooxygenase 1 _xmetabolism |
650 | 0 | 4 |
_aCyclooxygenase 2 _xmetabolism |
650 | 0 | 4 |
_aDrug Resistance _xdrug effects |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 | _aHalf-Life |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 | _aMale |
650 | 0 | 4 |
_aMetabolic Networks and Pathways _xdrug effects |
650 | 0 | 4 | _aMiddle Aged |
650 | 0 | 4 |
_aMolecular Targeted Therapy _xmethods |
650 | 0 | 4 |
_aProtein Biosynthesis _xdrug effects |
650 | 0 | 4 |
_aThrombocythemia, Essential _xdrug therapy |
650 | 0 | 4 |
_aThromboxane A2 _xbiosynthesis |
700 | 1 | _aPetrucci, Giovanna | |
700 | 1 | _aDragani, Alfredo | |
700 | 1 | _aHabib, Aida | |
700 | 1 | _aZaccardi, Francesco | |
700 | 1 | _aPagliaccia, Francesca | |
700 | 1 | _aPocaterra, Davide | |
700 | 1 | _aRagazzoni, Enzo | |
700 | 1 | _aRolandi, Giancarlo | |
700 | 1 | _aRocca, Bianca | |
700 | 1 | _aPatrono, Carlo | |
773 | 0 |
_tBlood _gvol. 119 _gno. 15 _gp. 3595-603 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1182/blood-2011-06-359224 _zAvailable from publisher's website |
999 |
_c21451363 _d21451363 |